Adlai Nortye Group Ltd. (ANL)
| Market Cap | 615.00M +1,011.1% |
| Revenue (ttm) | 18.06M |
| Net Income | -22.53M |
| EPS | -0.56 |
| Shares Out | 64.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 262,097 |
| Open | 10.11 |
| Previous Close | 10.28 |
| Day's Range | 9.36 - 10.13 |
| 52-Week Range | 0.88 - 17.25 |
| Beta | 1.11 |
| Analysts | Strong Buy |
| Price Target | 29.50 (+208.9%) |
| Earnings Date | Aug 14, 2026 |
About ANL
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (αPD-L1 x CD86 variant x LAG3 variant) t... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for ANL stock is "Strong Buy." The 12-month stock price target is $29.5, which is an increase of 208.90% from the latest price.
News
Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium
AN4035 late-breaking abstract selected for an oral presentation at the upcoming ENA Symposium in Barcelona Oral presentation will include translational and EGFR combination data for first-in-class AN4...
Adlai Nortye enters CTCSAs with Eli Lilly, Merck KGaA for cetuximab
Adlai Nortye (ANL) announced clinical trial collaboration and supply agreements, or CTCSAs, with Eli Lilly (LLY) and Merck KGaA (MKGAF) for the anti-EGFR antibody cetuximab. These agreements will supp...
Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
AN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the ongoing global Phase I trial
Adlai Nortye appoints Liu as Head of Investor Relations, Public Relations
Adlai Nortye (ANL) Group announced the appointment of Christopher Liu, PharmD, as Head of Investor Relations and Public Relations. Dr. Liu brings nearly a decade of equity research experience. Publish...
Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the d...
Adlai Nortye Group Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The event highlighted progress on two lead oncology assets: AN9025, a potent oral pan-RAS(ON) inhibitor in phase I trials with both daily and weekly dosing, and AN4035, a first-in-class ADC targeting CEACAM5. Key clinical data are expected in 2027, supported by a strong cash position.
Adlai Nortye initiated with a Buy at Jefferies
Jefferies analyst Maury Raycroft initiated coverage of Adlai Nortye (ANL) with a Buy rating and $31 price target AN9025 has a potentially best-in-class profile and the tolerability needed for first-li...
Adlai Nortye doses first patient in AN4035 trial
Adlai Nortye (ANL) announced that the first patient has been dosed with AN4035 in Australia, initiating the global Phase I trial in patients with CEACAM5-enriched RAS-addicted solid tumors. The compan...
Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC
First-in-class CEACAM5-targeting ADC armed with a pan-RAS(ON) inhibitor – designed for tumor-selective RAS pathway inhibition First patient dosed in Australia; global Phase I initiated U.S. FDA cleare...
Adlai Nortye assumed with a Buy at Lucid Capital
Lucid Capital assumed coverage of Adlai Nortye (ANL) with a Buy rating and price target of $49, up from $46. The firm believes AN9025, an oral pan-RAS(ON) inhibitor, has a…
Adlai Nortye Group Earnings release: Q2 2026
Adlai Nortye Group released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress
Enrollment ongoing in both QD and QW arms of global Phase I trial of pan-RAS(ON) inhibitor AN9025 First regulatory approval obtained for Phase I trial of pan-RAS(ON) ADC AN4035 Two leading medical onc...
Adlai Nortye submits clinical trial notification to Australia TGA for AN4035
Adlai Nortye (ANL) announced that it has submitted a clinical trial notification, or CTN, to Australia’s Therapeutic Goods Administration, or TGA, and received approval from the Human Research Ethics ...
Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia
First-in-class pan-RAS(ON) ADC is cleared for clinical development Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity. IND submissions to U.S. FDA and ...
Adlai Nortye doses first patient in AN9025 trial
Adlai Nortye (ANL) announced that the first patient has been dosed in the United States in the intermittent weekly dosing arm of the ongoing Phase 1 clinical trial of AN9025,…
Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
First patient dosed in intermittent QW dosing arm with AN9025 Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on prec...
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
SINGAPORE and NORTH BRUNSWICK, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the developm...
Cantor starts Adlai Nortye at Overweight, sees 180% upside
Cantor Fitzgerald initiated coverage of Adlai Nortye (ANL) with an Overweight rating without a price target The company has shifted focus to the RAS pathway in metastatic pancreatic ductal adenocarcin...
Adlai Nortye initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Adlai Nortye (ANL) with an Overweight rating.
Adlai Nortye Group Transcript: Jefferies Global Healthcare Conference 2026
Two RAS-targeted programs are advancing, with AN9025 in phase I and AN4035 ADC entering clinical studies in 2024. Intermittent dosing may widen the therapeutic window, and the ADC platform enables selective tumor targeting and rational combinations, especially in colorectal cancer.
Adlai Nortye initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Adlai Nortye (ANL) with an Outperform rating and $32 price target While the shares are up 770% year-to-date on a favorable read-through to AN9025 from Revolution…
Adlai Nortye initiated with a Buy at JonesResearch
JonesResearch analyst Boris Peaker initiated coverage of Adlai Nortye (ANL) with a Buy rating and $22 price target. Adlai had a recent recapitalization and refocus on pan-RAS(ON) inhibitors, which inc...
Adlai Nortye Group Registration statement: Registration filing
Adlai Nortye Group filed a registration statement on April 24, 2026, providing details about a securities offering with the SEC.
Adlai Nortye Group Registration statement: Registration filing
Adlai Nortye Group filed a registration statement on April 23, 2026, providing details about a securities offering with the SEC.
Adlai Nortye price target raised to $20 from $16 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Adlai Nortye (ANL) to $20 from $16 and keeps a Buy rating on the shares. The company’s lead asset,…